Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain by unknown
Wang et al. Cell Communication and Signaling 2014, 12:28
http://www.biosignaling.com/content/12/1/28RESEARCH Open AccessAutoinhibition of the Ron receptor tyrosine kinase
by the juxtamembrane domain
Xin Wang1, Neela Yennawar2 and Pamela A Hankey1,3*Abstract
Background: The Ron receptor tyrosine kinase (RTK) has been implicated in the progression of a number of
carcinomas, thus understanding the regulatory mechanisms governing its activity is of potential therapeutic
significance. A critical role for the juxtamembrane domain in regulating RTK activity is emerging, however the
mechanism by which this regulation occurs varies considerably from receptor to receptor.
Results: Unlike other RTKs described to date, tyrosines in the juxtamembrane domain of Ron are inconsequential
for receptor activation. Rather, we have identified an acidic region in the juxtamembrane domain of Ron that plays
a central role in promoting receptor autoinhibition. Furthermore, our studies demonstrate that phosphorylation of
Y1198 in the kinase domain promotes Ron activation, likely by relieving the inhibitory constraints imposed by the
juxtamembrane domain.
Conclusions: Taken together, our experimental data and molecular modeling provide a better understanding of
the mechanisms governing Ron activation, which will lay the groundwork for the development of novel
therapeutic approaches for targeting Ron in human malignancies.
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Dysregulated RTK activity is closely associated with a
broad range of human malignancies. Thereby, under-
standing the complex mechanisms by which RTKs are
regulated is of clinical significance due to potential ap-
plications for therapeutic intervention against cancers
[1,2]. Overexpression or constitutive activation of the
Ron receptor has been demonstrated to drive strong
oncogenic phenotypes in cancers derived from breast,
colon, lung, and prostate [3-5]. The oncogenic potential
of Ron is represented by its capacity to induce migration,
invasion, growth, survival and epithelial-mesenchamal
transition of epithelial tumor cells, as well as to promote
pro-tumoral activities of tumor-associated macrophages
[6-13]. Inhibition of Ron expression using Ron specific
siRNA dramatically decreases tumorigenic and invasive
activities in colorectal carcinoma cells [14]. A human* Correspondence: phc7@psu.edu
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reproduction in any medium, provided the orneutralizing antibody against Ron exhibits partial inhib-
ition of colon, lung and pancreatic tumor growth in xeno-
graft models [15], and a small molecule kinase inhibitor of
Ron that has antitumor activity in vivo has been described
[16]. Consequently, Ron is a promising target for the-
rapeutic intervention against tumorigenic activities and
malignant phenotypes [3,17,18].
Recepteur d'originenantais (Ron) (called STK in mice
and Sea in chickens) belongs to the Met proto-oncogene
family [19,20]. Originally synthesized as a single chain pre-
cursor, Ron is processed into a disulfide-linked heterodi-
mer with a transmembrane β chain and an extracellular α
chain [21,22]. Binding of macrophage stimulating protein
(MSP), the ligand for Ron, to the extracellular domain of
Ron induces receptor dimerization, conferring catalytic
activity to the receptor [23]. The intracellular region of
Ron includes the juxtamembrane domain, the highly
conserved kinase domain and the non-catalytic c-terminal
tail. The kinase domain consists of two lobes. The N-lobe
contains the αC helix and the P loop which are essential
for ATP recruitment, while phosphorylation of two tyro-
sines (Y1238 and Y1239) in the C-lobe activation loop is re-
quired for receptor activation. Subsequent phosphorylationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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variety of signaling pathways mediated by Ron [22,24]
(Figure 1A).
The juxtamembrane domain, which forms an import-
ant layer of constraint, limiting promiscuous enzymatic
activity of RTKs, is found frequently mutated in tumor
cells [25-32]. The regulatory mechanisms mediated by
the juxtamembrane domain however, varies significantly
due to the varied length and lack of sequence similarity
among RTKs. Murine Ron harboring a deletion of 27
residues in the juxtamembrane domain, caused by exclu-
sion of a potential exon, exhibits significantly higher
receptor activity than human Ron [33-36]. Deletion of
the 27 residues in human Ron promotes receptor activa-
tion, highlighting a potential role for the juxtamembrane
domain in the regulation of the Ron receptor activation
[33]. However, the molecular mechanisms underlying
this regulation are unknown.
Herein, we have characterized the mechanism by
which the juxtamembrane domain contributes to the
auto-regulation of Ron activity through structure/function
analysis. While tyrosines in the Ron juxtamembrane
domain are inconsequential for receptor activation, an
acidic JM-C region in the juxtamembrane domain was
found to be critical for Ron autoinhibition. Phosphoryl-
ation of Y1198 in the kinase domain promoted Ron activa-
tion, primarily by accelerating relief of the autoinhibitionFigure 1 Schematic diagram of the Ron receptor. A) Domains of the Ro
and activation loop (yellow) in the C lobe are denoted by different colors.
tail (P-Y: Y1353,1360) are indicated. B) The juxtamembrane domain of Ron is d
region at the N terminus; JM-B (1009–1035), the region corresponding to the
patch of residues; and JM-D (1048–1081), the region at the c-terminus of theimposed by the JM-C region. Based on our experimental
data, we have proposed molecular models of the inactive
and the active Ron structure, which cast a new light
on the mechanisms controlling Ron mediated signal
transduction.
Results
The acidic JM-C region in the Ron juxtamembrane domain
plays a critical role in receptor autoinhibition
The juxtamembrane domain of Ron is significantly
longer than that of most RTKs, therefore we divide it
into four sequential regions for clarity (Figure 1B). Pre-
vious studies have mapped the functional difference
between murine Ron and human Ron to the 27 residues
comprising the JM-B region, which contains Y1012 and
Y1017, the only two tyrosines in the juxtamembrane
domain (Additional file 1: Figure S1A). Tyrosines in the
juxtamembrane domain of RTKs such as the EphR, Flt3
and Kit [29,32,37] are critical for maintenance of the
inactive kinase, and phosphorylation of these tyrosines
relieves receptor autoinhibition. However, consistent
with previous reports [33,38], mutation of Y1012 and Y1017
individually or in combination into phenylalanine, glu-
tamic acid or alanine in the context of Ron did not affect
receptor autophosphorylation, downstream Erk phosphor-
ylation (Additional file 1: Figure S1B), or induction of AP1
luciferase activity (Additional file 1: Figure S1C). Thus,n receptor. P loop (orange) and αC helix (blue) in the kinase N lobe
Critical tyrosines in the activation loop (P-2Y: Y1238, 1239) and c-terminal
ivided into four sequential regions: JM-A (residue 982–1008), the
sequence deleted in mRon; JM-C (1036–1047), the region with an acidic
juxtamembrane domain. Residues discussed herein are indicated.
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main of Ron do not regulate receptor activation.
While the primary sequence differs, acidic residues
(glutamic acid and aspartic acid) interspersed with ser-
ines in the Ron JM-C region (Figure 2A) are relatively
conserved in the closely related Met receptor, suggesting
that this region might serve a conserved function. In
order to determine the potential role of this region in
the regulation of Ron receptor activity, we constructed a
Ron mutant in which nine residues (most acidic) in the
JM-C region were deleted (RonΔ1039–1047) (Figure 2A).
HA-tagged wild-type Ron and Ron variants were transi-
ently transfected in HEK 293 cells. Phosphorylation of
the activation loop tyrosines (Y1238/9), a hallmark of
kinase activation, and induction of a major signaling
cascade downstream of Ron, the Ras-Map kinase pathway,Figure 2 Acidic residues in the JM-C region of Ron promote
receptor autoinhibition. A) Schematic of mutants. Mutations are
highlighted in bold. Residues deleted are underlined. B) 293 cells
were transfected with HA-tagged wild-type or mutant Ron as
indicated in the presence and absence of MSP. Lysates were blotted
for p-Ron1238/9Y, HA, p-Erk, Erk and β-tubulin. C) Relative luciferase
activity in 293 cells co-transfected with wild-type or mutant Ron as
indicated, and an AP-1 luciferase reporter in the presence and
absence of MSP. The data were presented as the average ± standard
deviation from measurements collected from three independent
experiments and three measurements per experiment. Wild type
Ron −/+MSP was used as controls, unless denoted with ‘︹’. The
significant differences of values at p < 0.05, p < 0.01, and p < 0.001
levels are indicated by *, **and ***respectively.were examined. Ron and the variants were also transiently
transfected with an AP-1 luciferase reporter, and the
induced AP-1 transcriptional response was measured.
Equivalent levels of protein expression and cell surface
expression of Ron and its variants were demonstrated
by probing for HA and by the flow cytometry analysis
(Additional file 2: Figure S2), respectively. Compared
with the wild type receptor, RonΔ1039–1047 exhibited a
significant increase in receptor autophosphorylation,
induced Erk phosphorylation (Figure 2B) and AP-1
transcriptional activity both in the presence and absence
of MSP (Figure 2C). In order to further determine
whether the negative electrostatic nature of the JM-C
region is responsible for its role in the regulation of Ron
activity, E1044, D1045 and E1046 in the JM-C region were
mutated to alanine individually and in combination. Single
mutants did not show remarkable catalytic differences
compared with wild type Ron (data not shown). However,
the triple mutation (EDE-AAA) dramatically upregulated
receptor activity and downstream signaling to a level com-
parable to that induced by RonΔ1039–1047 (Figure 2B and C).
Based on these observations, we have identified a novel
segment in the juxtamembrane domain of Ron, the JM-C
region, which plays a central role in kinase autoinhibition,
primarily mediated by the acidic residues.
Serines (S1039,S1041,S1043,S1047) are major components
of the acidic JM-C region, the first three of which are
predicted to be potential phosphorylation sites (NetPhos
2.0 Server) (data not shown) (Figure 3A). In order to
determine whether phosphorylation of these serines
could play a role in the regulation of Ron receptor activity
by the JM-C region, we mutated the serines to alanines
individually and in combination. While individual and
double mutants performed similarly as wild-type Ron
(data not shown), the triple and quadruple mutations (3S-
A and 4S-A) resulted in an evident increase in receptor
activation and downstream signaling (Figure 3B and C).
However, this activation was not as striking as that driven
by mutations of the acidic 1044EDE residues. Thus, while
the acidic residues in the JM-C region maintain the pri-
mary inhibitory constraints, phosphorylation of serines in
this region may also contribute to the Ron autoinhibition
mediated by the JM-C region.
The JM-B region regulates receptor activity indirectly
through its impact on the spatial orientation of the JM-C
constraint
Previous studies demonstrated that deletion of the JM-B
region of human Ron (P1009-V1035), absent in murine
Ron, resulted in elevated receptor activity, as observed
in murine Ron [33]. However, our studies suggest that
individual residues in the JM-B region including tyro-
sines, are dispensable for Ron activation. Therefore, we
reasoned that the JM-B region might play a structural
Figure 3 Serines in the JM-C region play a subsidiary role in
the regulation of Ron receptor activation. A) Schematic of
mutants. Mutations are highlighted by underline. B) 293 cells were
transfected with HA-tagged wild-type or mutant Ron as indicated
in the presence and absence of MSP. Lysates were blotted for
p-Ron1238/9Y, HA, p-Erk and Erk. C) Relative luciferase activity in 293
cells co-transfected with wild-type or mutant Ron as indicated, and
an AP-1 luciferase reporter in the presence and absence of MSP.
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studies, here we found that RonΔJM-B possessed higher
intrinsic catalytic capability than the wild type receptor,
as demonstrated by a dramatic increase in phosphoryl-
ation of the activation loop tyrosines and a docking tyro-
sine, and in expression of an AP-1 reporter in both the
presence and the absence of ligand (Figure 4B and C). In
order to determine the significance of the length of the
JM-B region, a Ron variant with a smaller deletion of ten
residues (G1020-L1029) in the JM-B region, RonΔJM-B-S,
which did not result in deletion of the tyrosines in the
JM-B region, was constructed (Figure 4A). Surprisingly,
while RonΔJM-B exhibited enhanced receptor activity,
RonΔJM-B-S exhibited decreased receptor activity, and the
induced AP-1 transactivation was significantly reduced
even in the presence of MSP (Figure 4C and D). These
data indicate that the length of the JM-B region, rather
than individual residues, appears to be a critical deter-
minant for the proper regulation of Ron activity.
Since the acidic JM-C region lies c-terminal to the
JM-B region of Ron, we hypothesized that the JM-B
region might modulate receptor activity indirectly by
affecting localization of the JM-C region. In order totest this hypothesis, the EDE-AAA mutation in the
JM-C region was generated in the context of RonΔJM-B
and RonΔJM-B-S (Figure 4A). Since both ΔJM-B and EDE-
AAA were able to relieve Ron autoinhibition, as expected,
RonΔJM-B&EDE-AAA exhibited enhanced catalytic activity
both in the presence and absence of MSP (Figure 4D
and E). However, the levels of AP-1 luciferase activity
induced by RonΔJM-B&EDE-AAA were similar to those
induced by RonEDE-AAA, suggesting that the deletion of
JM-B region and neutralization of the acidic JM-C re-
gion may facilitate receptor activation in an analogous
manner. Alternatively, although the ΔJM-B-S deletion
prohibited receptor activation, introduction of the EDE-
AAA mutation into the RonΔJM-B-S construct largely re-
stored receptor activity (Figure 4D and E). Thus, it is likely
that the JM-B region modulates activation of the Ron re-
ceptor by affecting the spatial orientation of the adjacent
JM-C region, which places autoinhibitory constraints on
the kinase due to its electronegative characteristics.
Y1198 in the kinase domain mediates Ron autoinhibition
imposed by the JM-C region
Previous studies indicate that Y1194 in Met, the equi-
valent residue of Y1198 in Ron, is one of the three major
receptor autophosphorylation sites, and mutation of
Y1194 to phenylalanine in Met results in dramatically
decreased receptor activity [39,40]. Here we show that
the equivalent Y1198F mutation in Ron dramatically
reduced Ron autophosphorylation, as well as induction
of downstream Erk phosphorylation and AP-1 transcrip-
tional activation both in the presence and absence of
MSP (Figure 5B and C). These results indicate that
phosphorylation of Y1198 in the αE helix of the kinase C
lobe plays a key role in the activation of wild type Ron.
Although Y1198 and the juxtamembrane domain are
unlikely to sterically interact with each other based on
their distance, the potential functional interrelation was
evaluated by introduction of the Y1198F mutation in the
context of RonEDE-AAA and RonΔ1039–1047 (Figure 5A).
Alterations in the JM-C region, which were demonstrated
to relieve Ron autoinhibition, successfully rescued the loss
of receptor activity caused by the 1198Y-F mutation. The
double mutants recovered receptor activity to a level com-
parable to wild type Ron, and responded to stimulation by
MSP (Figure 5D and E). These studies suggest that phos-
phorylation of Y1198 may play an essential role in relieving
the inhibitory constraints on Ron activation imposed by
the JM-C region in an indirect manner.
Discussion
Mutations in the juxtamembrane domain are a common
mechanism by which RTKs become constitutively acti-
vated and drive progression of a variety of human cancers.





Figure 4 The JM-B region modulates Ron receptor activation by affecting the orientation of the JM-C region. A) Schematic of mutants.
Deletions of different lengths in the JM-B region are indicated by arrows. Mutated residues are highlighted in bold. B) & D) 293 cells were
transfected with HA-tagged wild-type or mutant Ron in the presence and absence of MSP. Lysates were immunoprecipitated with anti p-Y and
blotted for HA, or directly blotted for p-Ron1238/9, p-Ron1360 and HA, p-Erk and Erk. C) & E) Relative luciferase activity in 293 cells co-transfected
with wild-type or mutant Ron, and an AP-1 luciferase reporter in the presence and absence of MSP.
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myeloid leukemia [41]. Deletions in the juxtamembrane
domain of both KIT [42] and PDGFR [28] have been iden-
tified in human gastrointestinal stromal tumors. Germ line
point mutations in the juxtamembrane domain of Met
have been identified in small cell lung cancer [27] and
gastric cancer [43]. An alternatively spliced form of Met,
missing exon 14 which encodes part of its juxtamembrane
domain [44], exhibits a highly tumorigenic phenotype
[31,45]. Likewise, a splice variant of RON, missing exon
14 (BG289902) in the juxtamembrane domain, was found
in a bladder papilloma cell line (human Expressed
Sequence Tag data base). The juxtamembrane domain
of RTKs varies in length and lacks apparent sequence
similarity, suggesting that it may contribute to specific
aspects of regulation within individual receptor families.
Our studies demonstrate that, like other RTKs, the juxta-
membrane domain of Ron plays a central role in receptor
autoinhibition. However, the mode of regulation conferred
by the juxtamembrane domain of Ron appears to be novel
compared with other RTKs described to date.
Tyrosine phosphorylation in the juxtamembrane
domain of RTKs including Kit, Flt3 and EphR, is acommon mechanism by which the receptor switches
from the default closed state to an active configuration
[29,32,37,46]. However, phosphorylation and the aro-
matic side chain of tyrosines in the JM-B region are
dispensable for Ron activity. Conversely, deletions of
different lengths in the JM-B region were found to have
significant but opposite impacts on receptor activation,
probably through affecting the spatial orientation of the
contiguous JM-C region.
Here, we show that the acidic cluster in the JM-C re-
gion of Ron is a crucial regulator of receptor activity,
and disruption of its negative electrostatic property dra-
matically facilitates kinase activation. The acidic charac-
teristics of the JM-C region are relatively conserved
within the Met family members. The equivalent region
in Met was found to contain a mutation (S1058P) in a
sample from the non small cell lung cancer [47], sug-
gesting the potential functional significance of this
region. In order to better understand the inhibitory
mechanism imposed by the JM-C region, we compared
the kinase domain sequences of 150 receptors by mapping
them onto the crystal structure of the Ron kinase domain





Figure 5 Y1198 in the kinase domain of Ron regulates the autoinhibitory constraints on receptor activation imposed by the JM-C
region. A) Schematic of the Ron receptor. Y1198 at the interface of the αE helix and the αC helix is highlighted. B) & D) 293 cells were transfected
with HA-tagged wild-type or mutant Ron as indicated in the presence and absence of MSP. Lysates were blotted for p-Ron1238/9Y, HA, p-Erk
and Erk. C) & E) Relative luciferase activity in 293 cells co-transfected with wild-type or mutant Ron as indicated, and an AP-1 luciferase reporter in
the presence and absence of MSP.
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Ron kinase N lobe was identified as a putative JM-C bind-
ing region (orange in Figure 6A). It locates adjacent to the
strictly conserved active site (red in Figure 6A), with a pre-
dominantly positive surface potential (blue in Figure 6B).
Based on the crystal structure of the Ron kinase
domain, we built a molecular model of the inactive Ron
structure (including JM-C, JM-D region and kinase
domain) [48-51] (Additional file 3: Figure S3A), which
suggests that the JM-C region (magenta) promoting a
helical conformation could make close contacts with the
P loop (orange) and activation loop (yellow). Acidic
residues in the JM-C region (E1044-D1045-E1046) have the
potential to interact with H1092 in the P-loop, Y1238 and
Q1243 in the activation loop, and the side-chains of S1117
and R1118 between the β3 strand and the αC helix (lines
in Additional file 3: Figure S3A). These interactions
would interfere with the accommodation of ATP and
substrates by the glycine rich P-loop. Spatial proximityof the JM-C region could also lock the activation loop in
the inter-lobe cleft and prevent productive rotation of
the N and C lobe. In addition, the rigid configuration
promoted by the JM-C region, of the β3 strand and αC
helix in the kinase N lobe, puts the invariant K1114 and
E1130 that participate in formation of a salt bridge re-
quired for ATP binding in catalytically disfavored
positions.
Located at the interface between the αE and the αC
helix, Y1198 of Ron is highly conserved among RTKs and
shares structural conservation among close relatives in-
cluding Met, Ret, the insulin receptor, IGF1R and FGFR
[40,52-55]. Phosphorylation of the equivalent tyrosine in
Met and murine Ron is closely associated with receptor
activity [36,39,40]. In the crystal structure of the Ron
kinase domain [48], the nonproductive orientation of the
αC helix is held by two hydrogen bonds (Additional file 4:
Figure S4). One is between the side chain hydroxyl of
Y1198 in the αE helix and the backbone amide of N1139 at
Figure 6 Conserved surface residues and surface potential of
the Ron kinase domain (3PLS) [48]. The conserved region
adjacent to the active site with a predominantly positive surface
potential is indicated by arrows as the putative JM-C binding site.
A) Conserved residues on the surface of human kinase domains are
indicated, with red/orange representing highly conserved residues
and blue/cyan representing highly variable residues. B) Surface
potential of the Ron kinase domain, with blue representing positive
potential and red representing negative potential. The units of the
scale were −60.362 ~ 60.362.
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tween R1231 and Q1124 at the N-terminus. In order to fur-
ther understand the events leading to receptor activation,
we modeled the activated Ron kinase domain based on
the crystal structure of active Met (3Q6U) [56] (Additional
file 3: Figure S3B). In this model, the hydrogen bond
between Y1198 and N1139 is disrupted, potentially due to
the phosphorylation of Y1198. Consequently, the regional
stability of the inactive kinase domain collapses, and the
αC helix reorients significantly compared to its position in
the auto-inhibited model. This large scale movement
could promote the displacement of the JM-C constraint,
resulting in reorientation of the P-loop and activationloop, and realignment of the active site residues for re-
cruitment of ATP and substrates. Therefore, when Y1198 is
mutated to phenylalanine, the absence of phosphorylation
at this residue would be predicted to fix the αC helix in
the kinked non-productive orientation, stabilizing the
kinase in the inactive state. However, when the inhibitory
JM-C region is released by alterations in the juxtamem-
brane domain that disrupt the autoinhibition confered by
the juxtamembrane domain, phosphorylation of Y1198
would not be required for reorientation of the kinase seg-
ments and receptor activation.
Conclusions
Because the mode of regulation by the juxtamembrane
domain varies significantly among RTKs, targeting this
tier of regulation could provide an opportunity to de-
velop inhibitors that would exploit the unique aspects of
juxtamembrane domain regulation conferred upon indi-
vidual receptors. In that context, a synthesized peptide
representing the juxtamembrane domain of Kit is able to
impede receptor activation in vitro and delay growth of
cells containing an oncogenic form of Kit [37]. Alterna-
tively, targeting the autoinhibited form of the receptor
with small molecule inhibitors could provide an add-
itional level of specificity due to the association between
the juxtamembrane domain and the active site. The
work presented here has unveiled a novel regulatory
mechanism governing Ron activity by its juxtamembrane
domain, and provided a new perspective regarding the
regulation of RTK activity through conformational plas-
ticity and functional cooperation of different protein seg-
ments, which may provide important insights that could
lead to the development of a novel class of therapeutics
for the treatment against a wide range of Ron mediated
carcinomas.
Methods
Gene construction and mutagenesis
Human RON and mutants were expressed by the mam-
malian pcDNA3.1 vector or the murine stem cell virus
(MSCV) retroviral vector. Mutants were generated from
pcDNA-RON-HA or MSCV-RON-HA, with the Quik
Change mutagenesis kit (Stratagene) according to the
manufacturer’s instructions. The following PCR protocol
was used and primers for the mutants are listed in
Additional file 5: Table S1: 95°C 30 s, followed by 95°C
30 s, 55°C 1 min, 68°C 12 min for 20 cycles, and a final
68°C 12 min.
Cell culture, antibodies, and reagents
Human embryonic kidney (HEK) 293 cells (ATCC) were
maintained in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum. The TransIT-
293 transfection reagents were purchased from Mirus
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assay system was purchased from Promega Corporation
(Madison, WI). Antibodies against Ron 1238/9phospho-
tyrosine, phospho-Erk, Erk and the HA epitope (262 K)
were purchased from Cell Signaling. Goat anti-rabbit IgG-
HRP was purchased from Santa Cruz Biotechnology, Inc
(Santa Cruz, CA). Recombinant MSP was purchased from
R&D Systems. The AP-1 luciferase reporter cDNA was
kindly provided by Dr. Avery August (Cornell University).
All PCR primers were ordered from Eurofins MWG
Operon, Inc. (Huntsville, AL). Pfu Turbo DNA polymer-
ase was purchased from Agilent Tech. ECL Plus Western
blotting detection reagents were purchased from GE
Healthcare (Piscataway, NJ).
Cell transfection and luciferase assays
For the luciferase assay, 5 × 104 HEK 293 cells/well were
seeded into 24-well plates. Twenty four hours later, a
designated mixture of 60 ng of wild type or mutant
forms of RON, 60 ng of AP-1 luciferase reporter plas-
mid, and 0.5 ng renilla were used for transient transfec-
tion with the Mirus-293 transfection reagent according
to the manufacturer’s protocol. MSCV-neo or PCDNA3.1-
neo plasmid were used as control vectors for each trans-
fection. Cells were stimulated with 50 ng/ml (50 ug/ml
stock) MSP 24 h following transfection. Luciferase assays
were performed at 24 h later according to the manufac-
turer’s instructions (Promega). The fold increase is calcu-
lated as the firefly luciferase activity divided by the renilla
luciferase activity.
Western blot analysis
A total of 2.5 × 105HEK 293 cells/well were plated into
six-well plates. Twenty four hours later, the cells were
transiently transfected with 300 ng RON or its deriva-
tives per well. Cells were stimulated with 200 ng/ml
MSP for 48 h following transfection. 10 minutes later,
cells were suspended in 400 ul ice-cold cell lysis buffer
containing 150 mM NaCl, 20 mM Tris–HCl (pH 7.5),
5 mM EDTA, 1% NP-40, 1 mM phenylmethylsulfonyl
fluoride, 1 mM Na3VO4, and 10 mM NaF. Cell lysates
were centrifuged at 12,000 rpm for 20 min, and the
supernatant lysates were transferred to prechilled tubes.
Cell lysates were mixed with 4X denaturing SDS loading
buffer and heated at 100°C for 8 min. Samples were re-
solved on an SDS-PAGE gel and then transferred to
polyvinylidene difluoride membranes. Membranes were
then blocked with 5% nonfat milk or Bovine Serum
Albumin in Tris-buffered saline with 0.1% Tween 20
(TBST) for 1 h and probed with primary antibody at 4°C
overnight. Membranes were washed three times in TBST
and incubated with secondary goat anti-rabbit IgG-HRP
for another hour. Membranes were washed three times
in TBST before ECL plus Western blotting detectionreagents were applied for visualization. For reprobing,
membranes were stripped with 62.5 mM Tris–HCl
(pH 6.8), 2% SDS, and 0.7% β-mercaptoethanol at 55°C
for 30 min.Flow cytometry
A total of 1.2 × 105 HEK 293 cells/well were plated into
12-well plate. Twenty four hours later, the cells were
transiently transfected with 200 ng RON or its deri-
vatives per dish. PCDNA3.1-neo plasmid was used as
control vectors for each transfection. Flow cytometry
analysis was performed at 48 h later. 106 cells were incu-
bated per tube in 50 ul FACS buffer (ice cold PBS + 2%
FBS). Non-specific binding was blocked by the addition
of 50 μL HAB for 2 minutes at room temperature. Cells
were incubated on ice with 5 ug/ml anti-Ronβ (DX07)
or IgG (control) for 30 min. Cells were washed twice
with 1 ml FACS buffer and resuspended once more in
50 μL of FACS buffer. 50 μL HAB per tube was added
again for blocking of non-specific binding. Cells were
incubated with 5 ug/ml PE anti-mouse IgG1 as a second-
ary antibody to Ron for 30 min on ice. Cells were washed
twice, resuspended in 1 mL of FACS buffer and analyzed
for FLOW on a Beckman-Coulter FC500.Evaluation of surface conservation and potential
A comparison of 150 receptor kinase domain sequences
was mapped onto the crystal structure of the Ron
kinase domain (PDB code 3pls) using the CONSURF
web server. Surface conservation and surface potential of
the Ron kinase domain were illustrated. Potential JM-C
binding site was proposed based on residue/sequence
characteristics and relative distance.Molecular modeling of the JM-C region
Modeling of the autoinhibited and the activated con-
formation of Ron was based on the crystal structure of
the kinase domains of Ron (PDB code 3PLS) and Met
(PDB code 3Q6U) respectively. The modeling was done
manually using the COOT software [49]. Hydrogen
bonds between side chains were manually optimized and
the resultant model was energy minimized by using the
Yasara server [51].Structure-based sequence analysis
Seven algorithms, BPS [16], D_R [57], DSC [58], GGR
[59], GOR [60], G_G [61], H_K [62], K_S [63], L_G [64],
and Q_S [65], were used for secondary structure predic-
tion. The Joint prediction (JOI) is the prediction made
by the program that assigns the structure using a “win-
ner takes all” approach.
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Additional file 1: Figure S1. Tyrosines in the juxtamembrane
domain of Ron are dispensable for the regulation of receptor activity.
A) Schematic diagram of mutants. Y1012 and Y1017 in the JM-B region are
highlighted in bold. B) 293 cells were transiently transfected with HA-
tagged wild-type or mutant Ron in the presence and absence of MSP.
Lysates were blotted for p-Ron1238/9, HA, p-Erk and total Erk. C) Relative
luciferase activity in 293 cells co-transfected with wild-type or mutant
Ron, and an AP-1 luciferase reporter in the presence and absence of MSP.
Additional file 2: Figure S2. Cell surface expression of wild type Ron
and the Ron variants discussed herein. 293 cells were transiently
transfected with wild-type or mutated Ron as indicated. Cells were
harvested 48 h after transfection and analyzed by flow cytometry for
protein membrane expression.
Additional file 3: Figure S3. Predicted structure of the autoinhibited
and active form of Ron. A) In the inactive Ron model, the JM-C region
(magenta) is predicted to pack against and interact with the activation
loop (yellow) and P-loop (orange) near the active site of the kinase
domain. Potential bonds among residues in the JM-C region (1044EDE)
(magenta), the P loop (H1092) (orange), the active site (S1117, R1118) (green)
and the activation loop (E1237, Y1238) (yellow) are labeled with black
dashed lines. Y1198 (cyan stick) in the kinase C-lobe hydrogen bonds to
the backbone amide of N1139 at the c-terminus of the αC helix. B) In the
active Ron model, phosphorylation of Y1198 results in reorientation of the
αC helix and JM-D region. Consequently, the JM-C region is released from
the active site, which enables ATP binding and reorientation of the
activation loop. The orange and cyan stick represents AMP-PNP.
Figure was generated using the software Pymol.
Additional file 4: Figure S4. Y1198-N1139 hydrogen bond promotes the
non productive orientation of the αC helix. Crystal structure of the
autoinhibited Ron kinase domain (3PLS) is shown as cartoon. The αC
helix and αE helix are colored in cyan and green respectively. Residues
involved in the hydrogen bonds (yellow dash) linking the two helices are
labeled in white.
Additional file 5: Table S1. PCR primers for the mutant construction.
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